Kling Biotherapeutics

Executive Summary

Kling Biotherapeutics is a private Dutch biotechnology company pioneering antibody discovery through its proprietary Kling-Select and Kling-Evolve platforms. Based in Leiden and Amsterdam, Kling leverages patient-derived B cells to simultaneously identify novel targets and generate fully human antibodies, offering a superior path to first-in-class therapeutics. Founded in 2020, the company has built a wholly owned IP portfolio around its integrated discovery engine, which bypasses traditional immunization and library screening. While specific pipeline details are not publicly disclosed, Kling is currently advancing its lead candidate into Phase 1 clinical development, targeting an undisclosed oncology or immunology indication. The platform's ability to directly capture immune responses from patients positions Kling to address challenging targets with high specificity and low immunogenicity.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 trial for lead antibody candidate50% success
• TBDPotential strategic partnership or licensing deal for platform technology40% success
• Q3 2026Presentation of preclinical data at major scientific conference70% success